CABA Cabaletta Bio, Inc.

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.

$1.06
As of 07/01/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/25/2019
Outstanding shares:  28,977,129
Average volume:  171,193
Market cap:   $30,715,757
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BK5MWR1
Valuation   (See tab for details)
PE ratio:   -2.76
PB ratio:   0.26
PS ratio:   0.00
Return on equity:   -46.41%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy